Literature DB >> 30103646

Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort.

S-C Yang1, Y-Y Lai2, M-C Huang1, C-S Tsai3, J-L Wang4.   

Abstract

Objective This study investigated whether the incidence of opportunistic infection differed in systemic lupus erythematosus patients who received different doses of corticosteroids. Methods We included patients with diagnosed systemic lupus erythematosus from 1997 to 2010 using Taiwan national health insurance data. The index day for systemic lupus erythematosus patients was 3 months after the systemic lupus erythematosus diagnosis. A non-steroid cohort was matched 4:1 with the steroid cohort according to age, sex and index day. The end of the follow-up period was the day of opportunistic infection diagnosis, 1 year after the index day, or death. Results The overall cumulative incidence of opportunistic infection was 136-fold higher in the steroid cohort than in the non-steroid cohort. The adjusted hazard ratio for developing mycobacterium infection in the steroid cohort was 11, and the adjusted hazard ratio for developing herpes zoster was 43.6 compared to the non-steroid cohort after adjusting for immunosuppressive agents and comorbidities. The adjusted hazard ratio value for opportunistic infection was 1.40 (95% confidence interval (CI) 0.78-2.51) for a daily prednisone-equivalent dose of 7.5-15 mg, 1.72 (95% CI 1.02-2.91) for 15-30 mg, 1.96 (95% CI 1.17-3.28) for 30-60 mg and 2.24 (95% CI 1.26-4.00) for over 60 mg compared with low-dose steroids (<7.5 mg). Conclusion This study confirmed that the risk of opportunistic infection is higher in systemic lupus erythematosus patients treated with steroids in the first 3 months after diagnosis versus those not treated with steroids. Medium and high doses were associated with a higher risk of opportunistic infection compared with low doses. However, there was no controlling for disease activity, making it hard to know if increases in infection were due to disease itself or corticosteroids.

Entities:  

Keywords:  Corticosteroid dose; herpes zoster; mycobacterium infection; opportunistic infection; population study; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 30103646     DOI: 10.1177/0961203318792352

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  The Socioeconomic and Psychological Impact of the COVID-19 Pandemic on People with Multiple Sclerosis in Turkey.

Authors:  Tuncay Gündüz; Cihat Uzunköprü; Serkan Demir; Melih Tütüncü; Meral Seferoğlu; Haluk Gümüş; Sedat Şen; İpek Güngör Doğan; Mesude Tütüncü; Yasemin Solak Çalikoğlu; Yeşim Beckmann; Ayşe Sağduyu Kocaman; Aksel Siva
Journal:  Noro Psikiyatr Ars       Date:  2022-08-15       Impact factor: 1.066

2.  Tuberculosis Among Patients With Systemic Lupus Erythematosus in Indonesia: A Cohort Study.

Authors:  Laniyati Hamijoyo; Edhyana Sahiratmadja; Nadia G Ghassani; Guntur Darmawan; Evan Susandi; Reinout van Crevel; Philip C Hill; Bachti Alisjahbana
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

3.  Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.

Authors:  Chung-Yuan Hsu; Chi-Hua Ko; Jiun-Ling Wang; Tsai-Ching Hsu; Chun-Yu Lin
Journal:  Arthritis Res Ther       Date:  2019-10-12       Impact factor: 5.156

4.  Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China.

Authors:  Shangzhu Zhang; Meng Li; Li Zhang; Ziqian Wang; Qiang Wang; Hui You; Yanhong Wang; Mengtao Li; Xiaofeng Zeng
Journal:  J Immunol Res       Date:  2021-01-18       Impact factor: 4.818

Review 5.  Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  Kasra Molooghi; Fereshte Sheybani; Hamidreza Naderi; Zahra Mirfeizi; Negar Morovatdar; Ashkan Baradaran
Journal:  Lupus Sci Med       Date:  2022-01

6.  A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient.

Authors:  Kathy Hoang; Tony Abdo; J Matthew Reinersman; Rufei Lu; Nelson Iván Agudelo Higuita
Journal:  Med Mycol Case Rep       Date:  2020-05-30

7.  Varicella Vaccine Meningitis as a Complication of Herpes Zoster in Twice-Immunized Immunocompetent Adolescents.

Authors:  Veena Ramachandran; Stephen C Elliott; Kathie L Rogers; Randall J Cohrs; Miles Weinberger; Wallen Jackson; John E Carpenter; Charles Grose; Daniel J Bonthius
Journal:  J Child Neurol       Date:  2020-07-17       Impact factor: 1.987

8.  Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.

Authors:  Alemnew F Dagnew; Debora Rausch; Caroline Hervé; Toufik Zahaf; Myron J Levin; Anne Schuind
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580

Review 9.  COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.

Authors:  Alicia Rodriguez-Pla; Holenarasipur R Vikram; Vanood Khalid; Lewis J Wesselius
Journal:  Rheumatol Int       Date:  2021-06-06       Impact factor: 2.631

10.  Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.

Authors:  Dong Chen; Bo Yang; Yan Zhang; Liang Chen; Lai Wei; Weijie Zhang; Xinqiang Wang; Xiaolin Tong; Zhishui Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.